Molecular targeted therapies for indolent lymphomas: where are we?

G Saglio; G Parvis; M Bosa

doi:10.4081/hmr.v3i3.554

Abstracts

12 June 2009

Vol. 3 No. 3 (2009)

https://doi.org/10.4081/hmr.v3i3.554

Molecular targeted therapies for indolent lymphomas: where are we?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

PDF

228

Views

240

Downloads

Authors

G Saglio

support@pagepress.org

G Parvis

M Bosa

During the last decade the development of new drugs for the treatment of hematologic malignancies has become really promising. This innovative drug development is based on the translation into biochemical pharmacology of specific alterations of biological functions affecting tumour cells1. One of the most important examples is imatinib: it showed that it was possible to nullify the pathognomic genetic lesion of chronic myelogenous leukemia (CML). Drugs targeting unique disease-specific pathways have also found potential applicability in treating malignancies such as CD20-positive non-Hodgkin’s lymphoma (rituximab), follicular lymphoma (Bcl-2-targeted agents2-6) and other B-cell neoplasms (splenic tyrosine kinase [Syk] inhibitors;7-9 IkB kinase inhibitors10).